𝗢𝗻𝗲 𝗯𝗿𝗮𝗻𝗱. 𝗘𝘅𝗽𝗼𝗻𝗲𝗻𝘁𝗶𝗮𝗹 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Earlier today, we announced our transition to MindWalk™ (NASDAQ: HYFT). The vision is now reality: one brand uniting technology, data and science to reshape discovery.

Press release: ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”. Today, IPA (ImmunoPrecise Antibodies), along with BioStrand and Talem, unify under a single identity: MindWalk. This evolution marks more than a name change. It reflects a strategic

In this insightful blog by our data scientist, Sébastien Lemal, we explore AlphaFold 3’s potential and how BioStrand’s LENSᵃⁱ platform leverages these breakthroughs to accelerate biotherapeutic development. Read our blog: https://t.co/CU62yaue8u

2024: A Year of Transformative Progress in Biotherapeutics This year, we harnessed the power of the LENSᵃⁱ platform powered by proprietary HYFT™ pattern recognition technology and advanced simulations to tackle the most complex challenges in drug discovery. By combining

Catch Dr. Jennifer Bath's insightful Nasdaq interview with Jane King and Ari Zoldan, airing Saturday, September 28th! Dr. Bath explores how unlocking the full potential of integrated data and AI analytics is aimed at revolutionizing therapeutics research, enhancing patient

Data integration in #antibodydiscovery doesn’t have to be complex. With LENSᵃⁱ, streamline multi-omics data at the subsequence level for faster, sharper insights. From target discovery to lead optimization, we help you make informed decisions quickly. https://t.co/mvX6RHEBTb

Press Release: ImmunoPrecise Antibodies successfully engineers in silico antibodies to elusive tumor protein using its patented LENSᵃⁱ™ technology. "This marks a noteworthy milestone for the biotechnology industry, demonstrating LENSᵃⁱ's ability to engineer highly specific

In her latest blog, Julie Delanote, Data Scientist at BioStrand, explores how vector search and integrated AI technologies are transforming drug discovery by analyzing proteins at the sub-sequence level. Read the blog: https://t.co/cMQvYTdQI8

Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Platform API by BioStrand (IPA subsidiary). This game-changing API plugs directly into large pharma or biotech existing platforms, transforming their ability to

Our latest article explores how #insilico methods enhance #drugdevelopment by providing rapid insights, early identification of potential failures, and cost-effective streamlining. Read our blog: https://t.co/IIytXOxvA3 #BioStrandBlogs #Immunogenicity #DrugDiscovery $IPA

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenomic Recommendations Using LENSᵃⁱ™ "With more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict

In our latest blog post, Saskia Debergh, BioStrand computational linguist, explains why vector search is essential for finding precise information in vast data sets through advanced text analysis. Read more in our blog: https://t.co/vtR1KgDn9v $IPA #BioStrandBlogs

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery. The launch, led by Dr. Dirk Van Hyfte, highlights the integration of BioStrand's LENSᵃⁱ™, powered

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR). BioStrand is leveraging their patented Foundation AI Model, LENSᵃⁱ™, by applying advanced Large Language Models (LLM) to capture real world data from Electronic

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Technology. The 2024 Impact Award, sponsored by @InterSystems , acknowledges BioStrand’s innovative LENSᵃⁱ technology, selected from over 1,000 client

Our latest blog presents a detailed case study on the LENSᵃⁱ™ approach to in silico epitope binning, validated against traditional wet lab techniques. Discover how this innovation enhances scalability and accuracy in therapeutic mAb development. https://t.co/o5Vo9cZ0N0 $IPA

Discover how the collaboration between IPA subsidiary BioStrand and InterSystems is transforming technology and #drugdiscovery. Dirk Van Hyfte, BioStrand's Head of Innovation and Tom Dyar of InterSystems discuss the integration of BioStrand's LENSᵃⁱ Integrated Intelligence

Explore our latest article to see how this technique improves data retrieval across diverse #unstructureddata types. Learn about its applications in #drugdiscovery and #healthcare, and why it's crucial for modern data-driven solutions. Read now: https://t.co/8DJbUxTxDw $IPA

Edward steps into the role of Director of Sales Europe, bringing over two decades of experience in pharma and biotech. He will be focusing on guiding both BioStrand and IPA through exciting new research collaborations across Europe. Read his interview: